Monopar Therapeutics 8/9/2024 Earnings Report

Monopar Therapeutics EPS Results

• Actual EPS: -$0.10
• Consensus EPS: -$0.09
• Beat/Miss: Missed by -$0.01
• One Year Ago EPS: N/A

Monopar Therapeutics Revenue Results

• Actual Revenue: N/A
• Expected Revenue: N/A
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

Monopar Therapeutics Announcement Details

• Date: 8/9/2024
• Time: Before Market Opens
• Conference Call Date: N/A
• Conference Call Time: N/A

Monopar Therapeutics (NASDAQ:MNPR), Inc. is a clinical‐stage biotechnology company dedicated to developing novel targeted therapies for the treatment of cancer. The company’s research program focuses on exploiting unique vulnerabilities in tumor biology to enhance the efficacy and safety profile of its candidates. Monopar’s approach seeks to deliver precision medicines that address unmet needs in oncology by modulating the tumor microenvironment and leveraging insights into cancer stem cell biology.

Central to Monopar’s pipeline is MNPR-101, an orally administered small molecule designed to selectively bind and activate retinoic acid receptor pathways, aiming to induce differentiation of tumor cells while sparing healthy tissue. Additional assets in preclinical and early clinical stages include combination strategies that pair targeted inhibitors with immune modulators or standard chemotherapeutics. These programs reflect Monopar’s commitment to advancing therapies capable of improving long‐term outcomes for patients with solid tumors and hematologic malignancies.

Founded in 2014 and headquartered in San Francisco, Monopar maintains strategic collaborations with leading academic and research institutions across North America and Europe. These partnerships support the company’s translational efforts, enabling access to specialized clinical trials and biomarker platforms. Monopar’s multi‐site presence allows it to engage in diverse patient populations and accelerate enrollment in pivotal studies.

Under the leadership of Chief Executive Officer Domenico DiMarzo and Chief Scientific Officer Dr. Lee Rosen, Monopar has built a management team with extensive experience in oncology drug development, regulatory affairs, and commercialization. Guided by a board of directors and scientific advisory board comprised of industry veterans, the company continues to pursue its mission of delivering next‐generation cancer treatments to patients worldwide.